Eutilex
Korea - SeoulBiotechnology
Focus: Eutilex is a Seoul-based biotech company founded in 2017 specializing in T cell and antibody therapies. The company operates as a pre-revenue or early-stage clinical biotech with limited public disclosure of commercial operations.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Eutilex
AI assessmentNot HiringNo open roles listed right now. Follow Eutilex to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
EU103
Solid TumorClinical Trials (1)
NCT05798026A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
Phase 1Help build intelligence for Eutilex
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.